XBIO: Xenetic Biosciences Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Xenetic Biosciences Inc (XBIO).
$6.15M Market Cap.
XBIO Market Cap. (MRY)
XBIO Shares Outstanding (MRY)
XBIO Assets (MRY)
Total Assets
$6.90M
Total Liabilities
$894.26K
Total Investments
$0
XBIO Income (MRY)
Revenue
$2.50M
Net Income
-$3.96M
Operating Expense
$6.70M
XBIO Cash Flow (MRY)
CF Operations
-$2.82M
CF Investing
$0
CF Financing
$0
XBIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $6,901,443 (-34.92%) | $10,605,226 (-27.96%) | $14,720,290 (-25.71%) | $19,815,360 (50.35%) |
Assets Current | $6,587,522 (-31.29%) | $9,586,874 (-29.78%) | $13,653,359 (-27.08%) | $18,723,429 (51.37%) |
Assets Non-Current | $313,921 (-69.17%) | $1,018,352 (-4.55%) | $1,066,931 (-2.29%) | $1,091,931 (34.81%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $6,007,180 (-38.67%) | $9,795,641 (-28.22%) | $13,647,134 (-25.81%) | $18,394,257 (50.58%) |
Property Plant & Equipment Net | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Cash & Equivalents | $6,165,568 (-31.36%) | $8,983,046 (-31.41%) | $13,097,265 (-28.21%) | $18,244,030 (58.26%) |
Accumulated Other Comprehensive Income | $253,734 (0.00%) | $253,734 (0.00%) | $253,734 (0.00%) | $253,734 (0.00%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $283,615 (17.76%) | $240,832 (-16.19%) | $287,360 (-20.72%) | $362,470 (10.71%) |
Accumulated Retained Earnings (Deficit) | -$197,194,471 (-2.05%) | -$193,234,196 (-2.19%) | -$189,099,618 (-3.59%) | -$182,547,265 (-3.19%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Debt Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Debt Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Liabilities | $894,263 (10.46%) | $809,585 (-24.56%) | $1,073,156 (-24.48%) | $1,421,103 (47.42%) |
Liabilities Current | $894,263 (10.46%) | $809,585 (-24.56%) | $1,073,156 (-24.48%) | $1,421,103 (51.68%) |
Liabilities Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
XBIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $2,500,284 (-1.56%) | $2,539,986 (48.80%) | $1,706,925 (47.06%) | $1,160,692 (165.64%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $3,416,380 (-4.06%) | $3,560,936 (-2.55%) | $3,653,999 (-2.40%) | $3,743,972 (10.11%) |
Research & Development Expense | $3,288,332 (-5.91%) | $3,494,765 (-26.75%) | $4,770,834 (50.81%) | $3,163,485 (82.71%) |
Operating Expenses | $6,704,712 (-4.97%) | $7,055,701 (-16.25%) | $8,424,833 (21.97%) | $6,907,457 (-51.95%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$3,960,275 (4.22%) | -$4,134,578 (36.90%) | -$6,552,353 (-16.07%) | -$5,645,179 (48.18%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$3,960,275 (4.22%) | -$4,134,578 (36.90%) | -$6,552,353 (-16.07%) | -$5,645,179 (48.18%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$3,960,275 (4.22%) | -$4,134,578 (36.90%) | -$6,552,353 (-16.07%) | -$5,645,179 (48.18%) |
Weighted Average Shares | $1,541,339 (0.86%) | $1,528,210 (7.44%) | $1,422,443 (38.38%) | $1,027,941 (60.81%) |
Weighted Average Shares Diluted | $1,541,339 (0.86%) | $1,528,210 (7.44%) | $1,422,443 (38.38%) | $1,027,941 (60.81%) |
Earning Before Interest & Taxes (EBIT) | -$3,960,275 (4.22%) | -$4,134,578 (36.90%) | -$6,552,353 (-16.07%) | -$5,645,179 (59.13%) |
Gross Profit | $2,500,284 (-1.56%) | $2,539,986 (48.80%) | $1,706,925 (47.06%) | $1,160,692 (165.64%) |
Operating Income | -$4,204,428 (6.89%) | -$4,515,715 (32.78%) | -$6,717,908 (-16.90%) | -$5,746,765 (58.77%) |
XBIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | $0 (0%) | $0 (0%) | -$500,000 (0%) | $0 (0%) |
Net Cash Flow from Financing | $0 (0%) | $0 (0%) | $0 (0%) | $11,454,545 (111.07%) |
Net Cash Flow from Operations | -$2,817,478 (31.52%) | -$4,114,219 (11.46%) | -$4,646,765 (1.93%) | -$4,738,067 (-11.03%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$2,817,478 (31.52%) | -$4,114,219 (20.06%) | -$5,146,765 (-176.63%) | $6,716,478 (479.19%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | -$500,000 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $0 (0%) | $0 (0%) | $0 (0%) | $11,454,545 (111.07%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $171,814 (-39.31%) | $283,085 (-44.65%) | $511,480 (24.62%) | $410,437 (-12.47%) |
Depreciation Amortization & Accretion | $0 (0%) | $0 (0%) | $27,043 (-23.78%) | $35,482 (23.04%) |
XBIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% (0.00%) |
Profit Margin | -158.40% (2.70%) | -162.80% (57.59%) | -383.90% (21.07%) | -486.40% (80.49%) |
EBITDA Margin | -158.40% (2.70%) | -162.80% (57.42%) | -382.30% (20.90%) | -483.30% (84.68%) |
Return on Average Equity (ROAE) | -54.30% (-49.18%) | -36.40% (16.32%) | -43.50% (-14.47%) | -38.00% (54.92%) |
Return on Average Assets (ROAA) | -47.50% (-40.95%) | -33.70% (16.79%) | -40.50% (-14.41%) | -35.40% (50.00%) |
Return on Sales (ROS) | -158.40% (2.70%) | -162.80% (57.59%) | -383.90% (21.07%) | -486.40% (84.61%) |
Return on Invested Capital (ROIC) | -1523.70% (-263.56%) | -419.10% (64.03%) | -1165.20% (-15.69%) | -1007.20% (44.53%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -1.55 (-22.00%) | -1.27 (-105.32%) | -0.62 (73.56%) | -2.35 (-95.42%) |
Price to Sales Ratio (P/S) | 2.46 (18.50%) | 2.08 (-12.63%) | 2.38 (-79.20%) | 11.43 (-61.72%) |
Price to Book Ratio (P/B) | 1.02 (88.58%) | 0.54 (71.29%) | 0.32 (-66.24%) | 0.94 (-10.66%) |
Debt to Equity Ratio (D/E) | 0.15 (79.52%) | 0.08 (5.06%) | 0.08 (2.60%) | 0.08 (-2.53%) |
Earnings Per Share (EPS) | -2.57 (5.17%) | -2.71 (41.09%) | -4.6 (16.36%) | -5.5 (67.65%) |
Sales Per Share (SPS) | 1.62 (-2.41%) | 1.66 (38.50%) | 1.2 (6.29%) | 1.13 (65.06%) |
Free Cash Flow Per Share (FCFPS) | -1.83 (32.10%) | -2.69 (17.60%) | -3.27 (29.12%) | -4.61 (30.95%) |
Book Value Per Share (BVPS) | 3.9 (-39.20%) | 6.41 (-33.19%) | 9.59 (-46.38%) | 17.89 (-6.36%) |
Tangible Assets Book Value Per Share (TABVPS) | 4.48 (-35.48%) | 6.94 (-32.94%) | 10.35 (-46.31%) | 19.28 (-6.50%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | 1 (0.00%) | 1 (0%) | 0 (0%) |
Enterprise Value Over EBITDA (EV/EBITDA) | 0.17 (-83.97%) | 1.08 (-26.10%) | 1.46 (236.41%) | 0.43 (203.33%) |
Asset Turnover | 0.3 (44.93%) | 0.21 (97.14%) | 0.1 (43.84%) | 0.07 (160.71%) |
Current Ratio | 7.37 (-37.80%) | 11.84 (-6.92%) | 12.72 (-3.43%) | 13.18 (-0.20%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$2,817,478 (31.52%) | -$4,114,219 (11.46%) | -$4,646,765 (1.93%) | -$4,738,067 (-11.03%) |
Enterprise Value (EV) | -$686,425 (84.61%) | -$4,460,559 (53.17%) | -$9,524,175 (-291.58%) | -$2,432,237 (-142.01%) |
Earnings Before Tax (EBT) | -$3,960,275 (4.22%) | -$4,134,578 (36.90%) | -$6,552,353 (-16.07%) | -$5,645,179 (59.13%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$3,960,275 (4.22%) | -$4,134,578 (36.64%) | -$6,525,310 (-16.32%) | -$5,609,697 (59.30%) |
Invested Capital | -$158,388 (-119.49%) | $812,595 (47.78%) | $549,869 (266.03%) | $150,227 (-78.99%) |
Working Capital | $5,693,259 (-35.14%) | $8,777,289 (-30.23%) | $12,580,203 (-27.29%) | $17,302,326 (51.34%) |
Tangible Asset Value | $6,901,443 (-34.92%) | $10,605,226 (-27.96%) | $14,720,290 (-25.71%) | $19,815,360 (50.35%) |
Market Capitalization | $6,153,135 (15.76%) | $5,315,514 (22.93%) | $4,323,997 (-74.96%) | $17,270,492 (34.46%) |
Average Equity | $7,291,776 (-35.79%) | $11,356,375 (-24.64%) | $15,069,641 (1.39%) | $14,863,284 (15.04%) |
Average Assets | $8,343,717 (-31.93%) | $12,257,816 (-24.27%) | $16,186,257 (1.52%) | $15,944,416 (3.59%) |
Invested Capital Average | $259,919 (-73.65%) | $986,462 (75.42%) | $562,337 (0.33%) | $560,496 (-26.31%) |
Shares | 1,542,139 (0.09%) | 1,540,684 (1.58%) | 1,516,660 (13.29%) | 1,338,798 (112.63%) |
